SK287200B6 - C-21 modifikované epotilóny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a použitie - Google Patents

C-21 modifikované epotilóny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a použitie Download PDF

Info

Publication number
SK287200B6
SK287200B6 SK1078-2001A SK10782001A SK287200B6 SK 287200 B6 SK287200 B6 SK 287200B6 SK 10782001 A SK10782001 A SK 10782001A SK 287200 B6 SK287200 B6 SK 287200B6
Authority
SK
Slovakia
Prior art keywords
group
methyl
substituted
dihydroxy
alkyl group
Prior art date
Application number
SK1078-2001A
Other languages
English (en)
Slovak (sk)
Other versions
SK10782001A3 (sk
Inventor
Gerhard Hoefle
Nicole Glaser
Thomas Leibold
Gregory Vite
Soong-Hoon Kim
Original Assignee
Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf)
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999107588 external-priority patent/DE19907588A1/de
Priority claimed from DE1999130111 external-priority patent/DE19930111A1/de
Application filed by Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf), Bristol-Myers Squibb Company filed Critical Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf)
Publication of SK10782001A3 publication Critical patent/SK10782001A3/sk
Publication of SK287200B6 publication Critical patent/SK287200B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
SK1078-2001A 1999-02-22 2000-02-17 C-21 modifikované epotilóny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a použitie SK287200B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1999107588 DE19907588A1 (de) 1999-02-22 1999-02-22 C-21 Modifizierte Epothilone
DE1999130111 DE19930111A1 (de) 1999-07-01 1999-07-01 C-21 Modifizierte Epothilone
PCT/US2000/004068 WO2000050423A1 (en) 1999-02-22 2000-02-17 C-21 modified epothilones

Publications (2)

Publication Number Publication Date
SK10782001A3 SK10782001A3 (sk) 2002-03-05
SK287200B6 true SK287200B6 (sk) 2010-03-08

Family

ID=26051995

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1078-2001A SK287200B6 (sk) 1999-02-22 2000-02-17 C-21 modifikované epotilóny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a použitie

Country Status (37)

Country Link
US (1) US6262094B1 (ru)
EP (1) EP1157023B1 (ru)
JP (1) JP4598957B2 (ru)
KR (1) KR100685336B1 (ru)
CN (1) CN1205208C (ru)
AR (1) AR028815A1 (ru)
AT (1) ATE254615T1 (ru)
AU (1) AU771089B2 (ru)
BG (1) BG64987B1 (ru)
BR (1) BR0008379A (ru)
CA (1) CA2360452C (ru)
CO (1) CO5140093A1 (ru)
CZ (1) CZ301498B6 (ru)
DE (1) DE60006649T2 (ru)
DK (1) DK1157023T3 (ru)
EE (1) EE04852B1 (ru)
ES (1) ES2209831T3 (ru)
GE (1) GEP20033067B (ru)
HK (1) HK1038923B (ru)
HU (1) HUP0200076A3 (ru)
ID (1) ID29829A (ru)
IL (1) IL144501A0 (ru)
LT (1) LT4944B (ru)
LV (1) LV12755B (ru)
MX (1) MXPA01008374A (ru)
MY (1) MY120601A (ru)
NO (1) NO320806B1 (ru)
NZ (1) NZ513629A (ru)
PE (1) PE20001546A1 (ru)
PL (1) PL212545B1 (ru)
PT (1) PT1157023E (ru)
RU (1) RU2253652C2 (ru)
SK (1) SK287200B6 (ru)
TR (1) TR200102401T2 (ru)
TW (1) TWI270546B (ru)
UY (1) UY26024A1 (ru)
WO (1) WO2000050423A1 (ru)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ335383A (en) 1996-11-18 2000-10-27 Biotechnolog Forschung Gmbh Epothilone C,D,E and F for plant protection and cytostatic effects shown in kidney cells
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DE69734362T2 (de) * 1996-12-03 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
GB9810659D0 (en) * 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6589968B2 (en) * 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
MXPA03002521A (es) 2000-09-22 2004-02-12 Biotechnolog Forschung Gmbh Triazol-epotilona.
WO2002030356A2 (en) * 2000-10-13 2002-04-18 The University Of Mississipi Synthesis of epothilones and relates analogs
IL156580A0 (en) * 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
WO2002066038A1 (en) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
CA2438598A1 (en) * 2001-02-20 2002-08-29 Francis Y. F. Lee Epothilone derivatives for the treatment of refractory tumors
JP2004529904A (ja) 2001-03-14 2004-09-30 ブリストル−マイヤーズ　スクイブ　カンパニー 増殖性疾患の治療のためのエポシロン類似体および化学療法剤の組み合わせ
RU2346686C2 (ru) * 2002-01-14 2009-02-20 Новартис Аг Комбинации, включающие эпотилоны и антиметаболиты
TW200303202A (en) 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
US6900331B2 (en) * 2002-03-01 2005-05-31 University Of Notre Dame Derivatives of epothilone B and D and synthesis thereof
NZ535081A (en) * 2002-03-08 2007-05-31 Novartis Ag Combinations comprising epothilone derivatives and alkylating agents
SI1485090T1 (sl) * 2002-03-08 2008-06-30 Novartis Ag Kombinacija vključujoča derivat epotilona in imidazotetrazinon
ES2337134T3 (es) 2002-03-12 2010-04-21 Bristol-Myers Squibb Company Derivados de c3-ciano-epotilona.
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
AU2003227702B2 (en) * 2002-05-01 2007-07-26 Novartis Ag Epothilone derivative for the treatment of hepatoma and other cancer diseases
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
SI1767535T1 (sl) 2002-08-23 2010-03-31 Sloan Kettering Inst Cancer Sinteza epotilonov njihovih intermediatov analogov in uporaba le teh
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AU2003275068B2 (en) 2002-09-23 2009-09-17 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone B, and X-Ray crystal structures of epothilone B
RU2005114018A (ru) * 2002-10-09 2006-01-20 Козан Байосайенсиз, Инк. (Us) Эпотилон d+фторурацил/гемцитабин
ATE479667T1 (de) 2003-02-06 2010-09-15 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis
US20050171167A1 (en) 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
GB0405898D0 (en) 2004-03-16 2004-04-21 Novartis Ag Organic compounds
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
ES2306278T3 (es) * 2004-11-18 2008-11-01 Bristol-Myers Squibb Company Perla enterica recubierta que comprende ixabepilona.
US20060134214A1 (en) * 2004-11-18 2006-06-22 Ismat Ullah Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
EP1959952A4 (en) * 2005-11-22 2011-02-23 Scripps Research Inst CHEMICAL SYNTHESIS OF A VERY POWERFUL EPOTHILONE
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
BRPI0711591A2 (pt) 2006-05-16 2011-11-16 Aegera Therapeutics Inc composto de ligação de domìnio bir da iap
WO2008109075A2 (en) * 2007-03-05 2008-09-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
EP2152717A1 (en) * 2007-05-25 2010-02-17 Bristol-Myers Squibb Company Processes for making epothilone compounds and analogs
KR20100100949A (ko) 2008-01-08 2010-09-15 브리스톨-마이어스 스큅 컴퍼니 증식성 질환의 치료를 위한 튜불린 조정제와 항-ｃｔｌａ４ 항체의 조합물
EA021758B1 (ru) * 2008-04-24 2015-08-31 Бристол-Маерс Сквибб Компани Способ лечения болезни альцгеймера
JP2011525616A (ja) * 2008-05-29 2011-09-22 ブリストル−マイヤーズ スクイブ カンパニー 共刺激経路の調節に対する患者応答を予測するための方法
US8119129B2 (en) * 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
WO2011011027A1 (en) 2009-07-20 2011-01-27 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
DK2496567T3 (en) 2009-11-05 2017-10-30 Rhizen Pharmaceuticals S A PRESENT UNKNOWN BENZOPYRANKINA MODULATORS
SG182724A1 (en) 2010-02-12 2012-08-30 Pharmascience Inc Iap bir domain binding compounds
EP2571878B1 (en) 2010-05-17 2018-10-17 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases
WO2011146382A1 (en) 2010-05-17 2011-11-24 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
EA035193B1 (ru) 2010-05-18 2020-05-14 Серулин Фарма Инк. Композиции и способы лечения аутоиммунных и других заболеваний
RS58326B1 (sr) 2011-05-04 2019-03-29 Rhizen Pharmaceuticals S A Nova jedinjenja kao modulatori proteinskih kinaza
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
WO2013144737A2 (en) 2012-03-30 2013-10-03 Rhizen Pharmaceuticals Sa Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
EP2924044B1 (en) 2012-11-17 2018-10-31 Beijing Shuobai Pharmaceutical Co., LTD Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
EP3066127A1 (en) 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
BR112017011538A2 (pt) 2014-12-04 2018-03-13 Bristol-Myers Squibb Company combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma)
SI3313528T1 (sl) 2015-06-29 2021-11-30 Bristol-Myers Squibb Company Imunoterapevtski režim odmerjanja, ki vsebujejo pomalidomid in protitelo anti-CS1 za zdravljenje raka
CN105153177B (zh) * 2015-09-28 2017-08-08 湖南大学 呋喃并色满肟烯/炔丙基醚及其制备方法与应用
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE75883C (de) W. schulte in Siegen und F. A. SAPP in Hillnhütten, Kreis Siegen Ofen zur Erzeugung von Cyanammonium
DE301115C (ru)
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
ATE218556T1 (de) 1995-11-17 2002-06-15 Biotechnolog Forschung Gmbh Epothilon-derivate und deren herstellung
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
NZ335383A (en) * 1996-11-18 2000-10-27 Biotechnolog Forschung Gmbh Epothilone C,D,E and F for plant protection and cytostatic effects shown in kidney cells
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
DE69734362T2 (de) 1996-12-03 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
DE19707303B4 (de) 1997-02-11 2006-05-11 Mitteldeutsches Bitumenwerk Gmbh Verfahren zur Gewinnung von Mikrowachsen, Paraffinen und Ölen aus Altkunststoffen oder Altkunststoffgemischen
AU736062B2 (en) 1997-02-25 2001-07-26 Gesellschaft Fur Biotechnologische Forschung Mbh Epothilones which are modified in the side chain
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
DE59805900D1 (de) 1997-04-18 2002-11-14 Studiengesellschaft Kohle Mbh Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
DE59805727D1 (de) 1997-07-16 2002-10-31 Schering Ag Thiazolderivate, verfahren zur herstellung und verwendung
DK1005465T3 (da) 1997-08-09 2007-11-05 Bayer Schering Pharma Ag Nye epothilon-derivater, fremgangsmåde til fremstilling heraf og deres farmaceutiske anvendelse
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
AU754459B2 (en) * 1998-12-23 2002-11-14 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone

Also Published As

Publication number Publication date
TWI270546B (en) 2007-01-11
BG64987B1 (bg) 2006-11-30
NZ513629A (en) 2004-01-30
KR100685336B1 (ko) 2007-02-23
EE04852B1 (et) 2007-06-15
AU771089B2 (en) 2004-03-11
TR200102401T2 (tr) 2001-12-21
JP2002537395A (ja) 2002-11-05
HUP0200076A2 (hu) 2002-12-28
NO20014017D0 (no) 2001-08-17
BR0008379A (pt) 2002-09-24
LT2001086A (en) 2002-04-25
CA2360452C (en) 2011-07-26
NO20014017L (no) 2001-10-17
HK1038923B (zh) 2004-03-19
WO2000050423A1 (en) 2000-08-31
IL144501A0 (en) 2002-05-23
CN1341114A (zh) 2002-03-20
CO5140093A1 (es) 2002-03-22
US6262094B1 (en) 2001-07-17
PL350179A1 (en) 2002-11-18
EE200100437A (et) 2002-12-16
UY26024A1 (es) 2000-09-29
AU3234800A (en) 2000-09-14
EP1157023A1 (en) 2001-11-28
CZ301498B6 (cs) 2010-03-24
JP4598957B2 (ja) 2010-12-15
ID29829A (id) 2001-10-11
EP1157023B1 (en) 2003-11-19
LV12755B (lv) 2002-04-20
DE60006649D1 (de) 2003-12-24
RU2253652C2 (ru) 2005-06-10
KR20010102199A (ko) 2001-11-15
MY120601A (en) 2005-11-30
GEP20033067B (en) 2003-09-25
DE60006649T2 (de) 2004-09-30
CN1205208C (zh) 2005-06-08
CZ20012991A3 (cs) 2002-01-16
DK1157023T3 (da) 2004-03-29
PT1157023E (pt) 2004-03-31
CA2360452A1 (en) 2000-08-31
ATE254615T1 (de) 2003-12-15
LT4944B (lt) 2002-08-26
NO320806B1 (no) 2006-01-30
HK1038923A1 (en) 2002-04-04
PE20001546A1 (es) 2001-03-18
PL212545B1 (pl) 2012-10-31
AR028815A1 (es) 2003-05-28
BG105830A (en) 2002-03-29
MXPA01008374A (es) 2003-06-06
SK10782001A3 (sk) 2002-03-05
HUP0200076A3 (en) 2003-01-28
LV12755A (en) 2001-11-20
ES2209831T3 (es) 2004-07-01

Similar Documents

Publication Publication Date Title
SK287200B6 (sk) C-21 modifikované epotilóny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a použitie
US6291684B1 (en) Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
US6867305B2 (en) Synthesis of epothilones, intermediates thereto and analogues thereof
EP1483251B1 (en) C3-cyano epothilone derivatives
US20020058286A1 (en) Synthesis of epothilones, intermediates thereto and analogues thereof
JP2004500388A (ja) エポチロン、その中間体およびその類似体の合成
US8110590B2 (en) Synthesis of epothilones, intermediates thereto and analogues thereof
US7211593B2 (en) C12-cyano epothilone derivatives
AU4017400A (en) A process for the preparation of aziridinyl epothilones from oxiranyl epothilones
US6921769B2 (en) Synthesis of epothilones, intermediates thereto and analogues thereof

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20190217